What is Hexoskin?
Founded in 2006 and headquartered in Quebec, Canada, Hexoskin operates at the intersection of advanced hardware and predictive analytics. The firm specializes in the development of non-invasive sensors that capture high-fidelity physiological data, which is then processed through its proprietary software and AI services. This integrated ecosystem provides actionable insights for a diverse clientele, ranging from first responders and security personnel to pharmaceutical researchers and healthcare organizations. By bridging the gap between raw biometric data and clinical-grade intelligence, Hexoskin has established itself as a leader in the wearable technology market, particularly in environments where precision and reliability are non-negotiable.
How much funding has Hexoskin raised?
Hexoskin has raised a total of $5.5M across 2 funding rounds:
Angel/Seed
$1.3M
Other Financing Round
$4.2M
Angel/Seed (2015): $1.3M with participation from Anges Québec
Other Financing Round (2024): $4.2M led by BDC Capital Management, Anges Québec, and AQC Capital
Key Investors in Hexoskin
Anges Québec
Anges Québec is a prominent network of angel investors in Canada, dedicated to supporting passionate entrepreneurs and innovative projects through strategic guidance and value-added capital.
BDC Capital Management
BDC Capital Management is an independent investment advisory firm specializing in comprehensive financial planning and values-based investing to align strategies with long-term goals.
AQC Capital
AQC Capital is a venture firm focused on helping Quebec's most promising startup teams scale their operations and transform innovative ideas into global businesses.
What's next for Hexoskin?
With the successful closure of this major strategic investment, Hexoskin is well-positioned to accelerate its research and development initiatives, particularly in the refinement of its AI-driven diagnostic capabilities. The company is expected to scale its operations to meet the increasing demand for remote patient monitoring and high-performance physiological tracking in the aerospace and defense sectors. Furthermore, the infusion of capital will likely facilitate deeper penetration into international markets, allowing Hexoskin to expand its footprint as a global standard-bearer for health-tech innovation. As the company moves into this next phase of maturity, the focus will remain on enhancing the scalability of its data science services while maintaining the rigorous standards required by its enterprise and government partners.
See full Hexoskin company page
